PubMed Health⌕ Search

Biomedical subjects

U Larsson-Cohn

Publications and source records attributed to U Larsson-Cohn.

At least 37 records · Page 2Linked to original sources
PubMed1979

Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel.

Seventy-five menstruating women seeking contraceptive advice were randomly allocated to treatment with combined oral contraceptives containing either ethinyl estradiol 50 micrograms + levonorgestrel 250 micrograms (50/250), ethinyl estradiol 30 micrograms + levonorgestrel 150 micrograms (30/150) or ethinyl estradiol 50 micrograms + levonorgestrel 125 micrograms (50/125). The concentrations of cholesterol, triglycerides, phospholipids, high density lipoprotein (HDL)-cholesterol and HDL-phospholipids were determined after one, three and six months and compared to the mean of two determinations of the same parameters before medication. Triglycerides increased by 18--42 per cent after 1--6 months of treatment with 50/125. The HDL-cholesterol and HDL-phospholipids were reduced by 10 per cent during 50/250 treatment. No other parameters showed any consistent alteration in any of the treatment groups. Raised triglyceride concentration and/or decreased HDL concentration increases the risk for cardiovascular disease. It is therefore suggested that in order not to alter the HDL concentration a combined oral contraceptive agent should not contain more gestagen-androgen than corresponding to 125--150 micrograms of levonorgestrel. To avoid a rise of the triglyceride level the weight relation between levonorgestrel and ethinyl estradiol should be about 5:1.

Adult↗
PubMed1979

Effects of three different combinations of ethinyl estradiol and levonorgestrel on plasma lipids and high density lipoproteins.

Seventy-five menstruating women seeking contraceptive advice were randomly allocated to treatment with combined oral contraceptives containing either ethinyl estradiol 30 micrograms + levonorgestrel 150 micrograms (30/150), ethinyl estradiol 50 micrograms + levonorgestrel 125 micrograms (50/125) or ethinyl estradiol 50 micrograms + levonorgestrel 250 micrograms (50/250). The concentrations of cholesterol, phospholipids, high density lipoprotein (HDL)-cholesterol, HDL-phospholipids and triglycerides were determined prior to treatment and after one, three and six months of medication. Triglycerides increased by 18--42 per cent after one to six months of treatment with 50/125. The HDL-cholesterol and HDL-phospholipids were reduced by 10 per cent during 50/250 medication. No other parameters showed any consistent alteration in any of the treatment groups. Raised triglyceride concentration and/or decreased HDL concentration may increase the risk for cardiovascular disease. It is therefore suggested that in order not to alter the HDL concentration a combined oral contraceptive agent should probably not contain more 19-nortestosterone type of progestogen than corresponding to 125--150 micrograms of levonorgestrel. To avoid a rise of the triglyceride level the weight relation between levonorgestrel and ethinyl estradiol should be about 5:1.

Cholesterol↗
PubMed1978

Serum FSH, LH and oestrone levels in postmenopausal patients on oestrogen therapy.

Serum FSH, LH and oestrone levels were determined in postmenopausal women before and at 1, 3 and 6 months after the onset of cyclical treatment with 0.05 mg of ethinyl oestradiol (n = 19) or 2 mg of oestradiol valerianate (n = 20). Most samples from the women taking oestradiol valerianate were also analyzed for oestradiol. Vaginal smears were obtained from all patients. Although all women were relieved of vasomotor symptoms, the FSH levels usually exceeded the fertile range. Ethinyl oestradiol reduced FSH by 70 to 75 per cent and LH by 30 to 40 per cent while oestrone was increased by 20 to 40 per cent. In the women taking oestradiol valerianate, FSH and LH levels were both reduced by 20 to 25 per cent wheras serum oestradiol increased by 200 to 300 per cent and oestrone increased by 600 to 700 per cent. The mean vaginal maturation value rose equally in the two groups but 40 per cent of the patients in both groups showed no change in the value. There was no correlation between the appearance of vaginal endocrine smears and hormone levels.

Estradiol↗
PubMed1977

Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. I. Glucose, insulin and human growth hormone levels during oral glucose tolerance tests.

Glucose, insulin and growth hormone (GH) levels were measured during 3h oral glucose tolerance tests, performed in two groups of post-menopausal women. Nineteen subjects were given ethinyloestradiol (EOe) 0.05 mg daily and 20 received oestradiol valerinate (OeV) 2 mg daily. The tests were performed twice before treatment and after 1, 3 and 6 cycles of medication. EOe induced a slight but statistically significant deterioration of the glucose tolerance concomitant with a tendency to elevated insulin levels. The women taking OeV showed no significant alteration of the glucose or insulin levels. The GH concentrations were increased in both groups although the elevation was more pronounced in those taking EOe. The reduced carbohydrate tolerance was not believed to have been responsible for the raised GH levels.

Blood Glucose↗
PubMed1976

Differences between capillary and venous blood glucose during oral glucose tolerance tests.

The simultaneous capillary and venous blood glucose concentrations were measured during 36 oral glucose tolerance tests performed in 36 postmenopausal women. Three of the subjects had chemical diabetes mellitus. In samples obtained before and 120-180 min after the glucose load the differences between capillary and venous blood glucose concentrations were low, whereas samples taken after 15-90 min showed a mean capillary-venous difference of 1.8 mmol/l. This is higher than previously stated by the World Health Organization and the British Diabetes Association. If the definitions that were recommended by these two bodies are used for defining whether the result of an oral glucose tolerance test is to be considered 'normal' or 'abnormal', the present results indicate that the verdict will in some cases be influenced by the route by which the blood was obtained.

Blood Glucose↗
PubMed1975

Oral contraceptives and vitamins: a review.

The literature concerning the influence of estrogen-containing oral contraceptives on vitamins is reviewed. The appearance of an elevated plasma concentration of vitamin A is probably without clinical importance, while there seems to be a clear connection between disturbances of vitamin B6 metabolism and mental symptoms. Low levels of folic acid and vitamin B12 have also been noted. Despite this, it is very rare that hematologic abnormalities develop during hormonal contraception. A reduced concentration of vitamin C in plasma and blood corpuscles has been reported. The clinical significance of these alterations is unknown.

Ascorbic Acid↗